A. Aruga, S. Shu, and A. E. Chang, Tumor-speci®c granulocyte/ macrophage colony-stimulating factor and interferon gamma secretion is associated with in vivo therapeutic ecacy of activated tumor-draining lymph node cells, Cancer Immunol Immunother, vol.41, pp.317-324, 1995.

Y. Chin, J. Janssens, E. Smeyers, J. Bleus, J. Zhang et al., Large scale expansion of human tumor in®ltrating lymphocytes with surface-modi®ed stimulator cells for adoptive immuno, therapy Anticancer Res, vol.12, pp.733-736, 1992.

J. F. Fonteneau, L. Drean, E. , L. Guiner, S. Gervois et al., Heterogeneity of biologic responses of melanoma-speci®c CTL, J Immunol, vol.159, pp.2831-2839, 1997.

N. Gervois, Y. Guilloux, E. Diez, and F. Jotereau, Suboptimal activation of melanoma in®ltrating lymphocytes (TIL) due to low avidity of TCR/MHC-tumor peptide interactions, J Exp Med, vol.183, pp.2403-2407, 1996.

N. Gervois, F. Heuze, E. Diez, and F. Jotereau, Selective expansion of a speci®c anti-tumor CD8+ cytotoxic T lymphocyte clone in the bulk culture of tumor-in®ltrating lymphocytes from a melanoma patient: cytotoxic activity and T cell receptor gene rearrangements, Eur J Immunol, vol.20, pp.825-831, 1990.

N. Gervois, N. Labarriere, L. Guiner, S. Pandol®no, M. C. Fonteneau et al., High avidity melanoma-reactive cytotoxic T lymphocytes are eciently induced from peripheral blood lymphocytes on stimulation by peptide-pulsed melanoma cells, Clin Cancer Res, vol.6, pp.1459-1467, 2000.

W. Herr, J. Schneider, A. W. Lohse, M. Zum-buschenfelde, K. H. Wolfel et al., Detection and quanti®cation of bloodderived CD8+ T lymphocytes secreting tumor necrosis factor alpha in response to HLA-A2.1-binding melanoma and viral peptide antigens, J Immunol Methods, vol.191, pp.131-142, 1996.

Y. Itoh and R. N. Germain, Single cell analysis reveals regulated hierarchical T cell antigen receptor signaling thresholds and intraclonal heterogeneity for individual cytokine responses of CD4+ T cells, J Exp Med, vol.186, pp.757-766, 1997.

F. Jotereau, M. C. Pandol®no, D. Boudart, E. Diez, B. Dreno et al., High-fold expansion of human cytotoxic T-lymphocytes speci®c for autologous melanoma cells for use in immunotherapy, J Immunother, vol.10, pp.405-411, 1991.

T. Jung, U. Schauer, C. Heusser, C. Neumann, and C. Rieger, Detection of intracellular cytokines by¯ow cytometry, J Immunol Methods, vol.159, pp.197-207, 1993.

Y. Kawakami, N. Dang, X. Wang, J. Tupesis, P. F. Robbins et al., Recognition of shared melanoma antigens in association with major HLA-A alleles by tumor in®ltrating T lymphocytes from 123 patients with melanoma, J Immunother, vol.23, pp.17-27, 2000.

N. Labarriere, E. Diez, M. C. Pandol®no, C. Viret, Y. Guilloux et al., Optimal T cell activation by melanoma cells depends on a minimal level of antigen transcription, J Immunol, vol.158, pp.1238-1245, 1997.
URL : https://hal.archives-ouvertes.fr/inserm-02482164

N. Labarriere, M. C. Pandol®no, D. Raingeard, L. Guiner, S. Diez et al., Frequency and relative fraction of tumor antigen-speci®c T cells among lymphocytes from melanoma-invaded lymph nodes, Int J Cancer, vol.78, pp.209-215, 1998.

D. H. Lynch and R. E. Miller, Immunotherapeutic elimination of syngeneic tumors in vivo by cytotoxic T lymphocytes generated in vitro from lymphocytes from the draining lymph nodes of tumor-bearing mice, Eur J Immunol, vol.21, pp.1403-1410, 1991.

C. J. Melief and W. M. Kast, T-cell immunotherapy of tumors by adoptive transfer of cytotoxic T lymphocytes and by vaccination with minimal essential epitopes, Immunol Rev, vol.145, pp.167-177, 1995.

M. Nagoshi, P. S. Goedegebuure, U. L. Burger, N. Sadanaga, M. P. Chang et al., Successful adoptive cellular immunotherapy is dependent on induction of a host immune response triggered by cytokine (IFN-gamma and granulocyte/ macrophage colony-stimulating factor) producing donor tumor-in®ltrating lymphocytes, J Immunol, vol.160, pp.334-344, 1998.

M. C. Pandol®no, C. Viret, N. Gervois, Y. Guilloux, F. Davodeau et al., Speci®city, T cell receptor diversity and activation requirements of CD4+ and CD8+ clones derived from human melanoma-in®ltrating lymphocytes, Eur J Immunol, vol.22, pp.1795-1802, 1992.

M. J. Pittet, D. Valmori, P. R. Dunbar, D. E. Speiser, D. Lienard et al., High frequencies of naive Melan-A/MART-1-speci®c CD8(+) T cells in a large proportion of human histocompatibility leukocyte antigen (HLA)-A2 individuals, J Exp Med, vol.190, pp.705-715, 1999.

P. Romero, P. R. Dunbar, D. Valmori, M. Pittet, G. S. Ogg et al., Ex vivo staining of metastatic lymph nodes by class I major histocompatibility complex tetramers reveals high numbers of antigen-experienced tumor-speci®c cytolytic T lymphocytes, J Exp Med, vol.188, pp.1641-1650, 1998.

S. A. Rosenberg, B. S. Packard, P. M. Aebersold, D. Solomon, S. L. Topalian et al., Use of tumor-in®ltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma, N Engl J Med, vol.319, pp.1676-1680, 1988.

S. A. Rosenberg, J. R. Yannelli, J. C. Yang, S. L. Topalian, D. J. Schwartzentruber et al., Treatment of patients with metastatic melanoma with autologous tumor-in®ltrating lymphocytes and interleukin 2, J Natl Cancer Inst, vol.86, pp.1159-1166, 1994.

D. J. Schwartzentruber, S. S. Hom, R. Dadmarz, D. E. White, J. R. Yannelli et al., vitro predictors of therapeutic response in melanoma patients receiving tumor-in®ltrating lymphocytes and interleukin, 1994.

, J Clin Oncol, vol.12, pp.1475-1483

M. H. Tessier, M. C. Pandol®no, F. Jotereau, D. Boudart, P. Litoux et al., Home therapy with autologous tumour-in®l-trating lymphocytes and subcutaneous interleukin-2 in metastatic melanoma, Eur J Cancer, vol.32, pp.735-736, 1996.

S. L. Topalian, L. M. Muul, D. Solomon, and S. A. Rosenberg, Expansion of human tumor in®ltrating lymphocytes for use in immunotherapy trials, J Immunol Methods, vol.102, pp.127-141, 1987.

S. L. Topalian, D. Solomon, and S. A. Rosenberg, Tumor-spe-ci®c cytolysis by lymphocytes in®ltrating human melanomas, J Immunol, vol.142, pp.3714-3725, 1989.

C. Yee, P. A. Savage, P. P. Lee, M. M. Davis, and P. D. Greenberg, Isolation of high avidity melanoma-reactive CTL from heterogeneous populations using peptide-MHC tetramers, J Immunol, vol.162, pp.2227-2234, 1999.